GlobeNewswire
-
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17/11/2026 -
PacBio to Participate in the Piper Sandler 38th Annual Healthcare Conference
17/11/2026 -
CVRx to Participate at the Piper Sandler 38th Annual Healthcare Conference
17/11/2026 -
Dazed, Inc. Reports 72.5% Gross Margin and 121% Royalty Growth as Texas Lawmakers File Adult-Use Cannabis Bills in Home Market
17/11/2026 -
Newly Launched CuraeChoice Platform Unlocks Healthcare Pricing Visibility for Nearly 370,000 Employers by Tax ID Alone
17/11/2026 -
Terumo Neuro Announces Publication of RESTORE Registry Results in the Journal of NeuroInterventional Surgery
17/11/2026 -
Davion Healthcare Plc Provides Shareholders with Guidance on Direct Registration and Confirmation of Share Ownership
17/11/2026 -
Nine-month interim report (Q3) 2026 (unaudited)
17/11/2026 -
Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update
17/11/2026 -
Firefly Neuroscience Reports 373% Year-Over-Year Increase in U18 ADHD Evoke™ Scans as Commercial Expansion Accelerates
17/11/2026 -
Senti Bio Announces Reverse Stock Split
17/11/2026 -
Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion
17/11/2026 -
MIRA Pharmaceuticals Reports New MIRA-55 Selectivity Findings Supporting a Differentiated Non-Opioid Approach to Pain
17/11/2026 -
BetterLife Pharma Announces Stock Option Grant
17/11/2026 -
Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering
17/11/2026 -
Daxor Expands Midwest Footprint with Launch of ezBVA Lab Program at Premier Kansas Academic Medical Center
17/11/2026 -
La campagne Raise Craze de la Fondation du CUSM recueille 115 765 $ pour les soins contre le cancer du sein au CUSM
17/11/2026 -
The MUCH Foundation’s Raise Craze raises $115,765 for breast cancer care at the MUHC
17/11/2026 -
Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study
17/11/2026
Pages